Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Enzyme-mediated depletion of methylthioadenosine restores T cell function in MTAP-deficient tumors and reverses immunotherapy resistance
Donjeta Gjuka, Elio Adib, Kendra Garrison, et al.
Cancer Cell (2023) Vol. 41, Iss. 10, pp. 1774-1787.e9
Closed Access | Times Cited: 21

Showing 21 citing articles:

Revisiting Treatment of Metastatic Urothelial Cancer: Where Do Cisplatin and Platinum Ineligibility Criteria Stand?
Mohammad Jad Moussa, Matthew T. Campbell, Omar Alhalabi
Biomedicines (2024) Vol. 12, Iss. 3, pp. 519-519
Open Access | Times Cited: 11
Further knowledge and developments in resistance mechanisms to immune checkpoint inhibitors
Léa Berland, Zeina Gabr, Michelle Chang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 9
Tumor cell metabolic reprogramming and hypoxic immunosuppression: driving carcinogenesis to metastatic colonization
Theodora Katopodi, Savvas Petanidis, Doxakis Anestakis, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 8
Context-dependent effects of CDKN2A and other 9p21 gene losses during the evolution of esophageal cancer
Piyali Ganguli, Celia De Los Angeles Colomina Basanta, Amelia Acha‐Sagredo, et al.
Nature Cancer (2025)
Open Access | Times Cited: 1
Methionine intervention induces PD-L1 expression to enhance the immune checkpoint therapy response in MTAP-deleted osteosarcoma
Haoran Mu, Qí Zhāng, Dongqing Zuo, et al.
Cell Reports Medicine (2025), pp. 101977-101977
Open Access
Unlocking the mechanisms underlying the activity of pembrolizumab plus enfortumab vedotin in patients with urothelial carcinoma
Matteo Santoni, Alessandro Rizzo, Francesco Massari
Expert Opinion on Investigational Drugs (2025)
Closed Access
Loss of MTAP Expression by Immunohistochemistry Is a Surrogate Marker for Homozygous 9p21.3 Deletion in Urothelial Carcinoma
Tatjana Vlajnic, Obinna Chijioke, Luca Roma, et al.
Modern Pathology (2024) Vol. 37, Iss. 6, pp. 100495-100495
Closed Access | Times Cited: 4
MTA-cooperative PRMT5 inhibitors enhance T cell-mediated antitumor activity in MTAP-loss tumors
Si Chen, Jiakai Hou, Roshni Jaffery, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 9, pp. e009600-e009600
Open Access | Times Cited: 4
MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: a phase I trial
Mrinal M. Gounder, Melissa L. Johnson, Rebecca S. Heist, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
PRMT5 inhibitors: Therapeutic potential in pancreatic cancer
Carolin Schneider, Valentina Spielmann, Christian Braun, et al.
Translational Oncology (2025) Vol. 55, pp. 102366-102366
Closed Access
A gut microbiota rheostat forecasts responsiveness to PD-L1 and VEGF blockade in mesothelioma
Min Zhang, Aleksandra Bzura, Essa Y. Baitei, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 3
Prevalence of S-methyl-5′-thioadenosine Phosphorylase (MTAP) Deficiency in Human Cancer
Natalia Gorbokon, Niklas Wößner, Maximilian Lennartz, et al.
The American Journal of Surgical Pathology (2024) Vol. 48, Iss. 10, pp. 1245-1258
Open Access | Times Cited: 2
Context-dependent effects of CDKN2A and other 9p21 gene losses during the evolution of oesophageal cancer
Piyali Ganguli, Celia De Los Angeles Colomina Basanta, Amelia Acha‐Sagredo, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
MTAP as an emerging biomarker in thoracic malignancies
Magdalena M. Brune, Spasenija Savic Prince, Tatjana Vlajnic, et al.
Lung Cancer (2024) Vol. 197, pp. 107963-107963
Open Access | Times Cited: 1
Loss of MTAP expression is strongly linked to homozygous 9p21 deletion, unfavorable tumor phenotype, and noninflamed microenvironment in urothelial bladder cancer
Natalia Gorbokon, Niklas Wößner, Viktoria Ahlburg, et al.
The Journal of Pathology Clinical Research (2024) Vol. 11, Iss. 1
Open Access | Times Cited: 1
Deep Learning Model for Predicting Immunotherapy Response in Advanced Non−Small Cell Lung Cancer
Mehrdad Rakaee, Masoud Tafavvoghi, Biagio Ricciuti, et al.
JAMA Oncology (2024)
Closed Access | Times Cited: 1
5’-S-(3-aminophenyl)-5’-thioadenosine, a novel chemoprotective agent for reducing toxic side effects of fluorouracil in treatment of MTAP-deficient cancers
Si Zhang, Hui Xue, Nelson K.Y. Wong, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Methionine Intervention Induces PD-L1 Expression to Enhance the Immune Checkpoint Therapy Response in MTAP-Deleted Osteosarcoma
Haoran Mu, Qi Zhang, Dongqing Zuo, et al.
(2024)
Closed Access
Genetically predicted metabolites mediate the association between immune cells and metabolic dysfunction-associated steatotic liver disease: a mendelian randomization study
Dan Ye, Jiaofeng Wang, Jiaheng Shi, et al.
Lipids in Health and Disease (2024) Vol. 23, Iss. 1
Open Access
The Tumor Metabolite 5′-Deoxy-5′Methylthioadenosine (MTA) Inhibits Maturation and T Cell-Stimulating Capacity of Dendritic Cells
Christina Brummer, Katrin Singer, Frederik Henrich, et al.
Cells (2024) Vol. 13, Iss. 24, pp. 2114-2114
Open Access
Turning on anti-tumour T cells via MTAP
Yvonne Bordon
Nature reviews. Immunology (2023) Vol. 23, Iss. 11, pp. 703-703
Closed Access
Page 1

Scroll to top